DiscoveryBioMed Awarded Phase 2 SBIR Grant by the NIH

DiscoveryBioMed, Inc. has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH).
The company, which is located within the Innovation Depot facility in Birmingham, Alabama, has received the grant to continue its research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.
Commenting on the financing, Dr. Erik Schwiebert, Chief Executive Officer of DiscoveryBioMed was reported as saying: “We are proud to have been awarded this grant and to have our technology again recognized and validated by the NIH.
“With our academic partners at the University of Alabama at Birmingham and at Johns Hopkins University School of Medicine, we stand ready to test lead compounds for safety and efficacy in both CF and hypertensive animal models”.

Join the discussion